Featured Article

Comparative Effectiveness of Glucagon Like Peptide 1 Receptor Agonists - the ultimate collection

Heather Aug 05, 2026

Comparative Effectiveness of Glucagon

Comparative Effectiveness of Glucagon Like Peptide 1 Receptor Agonists
Comparative Effectiveness of Glucagon Like Peptide 1 Receptor Agonists

This study aimed to compare the effectiveness of 2 drug classes, glucagon-like peptide-1 receptor agonists and sodium/glucose cotransporter 2 inhibitors, in preventing kidney failure and death in patients with type 2 diabetes and chronic kidney disease.

Glucagon Like Peptide 1 Receptor Agonists and Heart Failure
Glucagon Like Peptide 1 Receptor Agonists and Heart Failure

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular, kidney, and survival outcomes in patients with type 2 diabetes; however, the comparative effectiveness of these drugs in a real-world setting remains unclear.

Comparative Effectiveness of Glucagon

Perioperative Considerations for Patients on GLP1 Agonists Advances
Perioperative Considerations for Patients on GLP1 Agonists Advances

Abstract Background: Addition of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to basal insulin can decrease insulin requirements, but whether it permits insulin discontinuation is unclear.

Tirzepatide is a new glucagon-like peptide-1 receptor agonist (GLP-1RA) that has shown promising results for weight loss. A Bayesian network meta-analysis was conducted to compare the efficacy and sa...

Frontiers
Frontiers

Comparative Cardiovascular Effectiveness of Glucagon

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2Is) have established cardiovascular benefits for patients with type 2 diabetes mellitus (T2DM), with similar class-level effectiveness found in previous studies. However, real-world comparative effectiveness assessments of individual agents remain limited.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown beneficial effects on clinical outcomes in patients with heart failure (HF) with preserved ejection fraction (HFpEF) or minimally reduced ejection fraction (HFmrEF). This network meta-analysis (NMA) aimed to consolidate evidence from RCTs assessing the effects of GLP-1 RAs in HFpEF and HF with reduced ejection fraction.

SGLT2 Inhibitors vs GLP 1 Agonists to Treat the Heart the Kidneys
SGLT2 Inhibitors vs GLP 1 Agonists to Treat the Heart the Kidneys

Comparative effectiveness of glucagon

Background To date, no studies have addressed the comparative efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RAs) therapy on body composition and anthropometric indices among adult overweight or obese patients with or without type 2 diabetes. To provide evidence-based recommendations, we will conduct a traditional pairwise and network meta-analysis of all available randomized ...

Background To date, no studies have addressed the comparative efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RAs) therapy on body composition and anthropometric indices among adult overweight or obese patients with or without type 2 diabetes. To provide evi-dence-based recommendations, we will conduct a traditional pairwise and network meta-analysis of all available randomized ...

Brasil Kidney effects of Glucagon Like Peptide 1 GLP1
Brasil Kidney effects of Glucagon Like Peptide 1 GLP1

Comparative cardiovascular effectiveness of glucagon

This study aimed to assess the comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) across diverse ASCVD phenotypes.

GLP 1 Receptor Agonists and Kidney Protection
GLP 1 Receptor Agonists and Kidney Protection
GLP 1 receptor agonists GLP 1RAs cardiovascular actions
GLP 1 receptor agonists GLP 1RAs cardiovascular actions
glp1 糖尿病 glp 1製剤とは OGEGK
glp1 糖尿病 glp 1製剤とは OGEGK
Translated article Glucagon Like Peptide 1 Agonists for Treating
Translated article Glucagon Like Peptide 1 Agonists for Treating

The comparative effectiveness of glucagon-like peptide-1 (GLP-1) agonists , dipeptidyl peptidase-4 (DPP-4) inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes mellitus (T2DM) is unknown.